Is the FDA Too Cautious?

While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?  Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia    Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest   Emmy award-winning journalist John Donvan moderates    Learn more about your ad choices. Visit podcastchoices.com/adchoices

Om Podcasten

America is more divided than ever—but it doesn’t have to be. Open to Debate offers an antidote to the chaos. We bring multiple perspectives together for real, nonpartisan debates. Debates that are structured, respectful, clever, provocative, and driven by the facts. Open to Debate is on a mission to restore balance to the public square through expert moderation, good-faith arguments, and reasoned analysis. We examine the issues of the day with the world’s most influential thinkers spanning science, technology, politics, culture, and global affairs. It’s time to build a stronger, more united democracy with the civil exchange of ideas. Be open-minded. Be curious. Be ready to listen. Join us in being Open to Debate. (Formerly Intelligence Squared U.S.)